- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
ACHN Market Currents
more »
-
May 21 Achillion (ACHN +10.4%), possibly because of the release of positive results from a Phase Ib trial of ACH-2684 for the Treatment of Hepatitis C. Last week, the FDA fast-tracked ACH-3102, also for Hepatitis C. (PR)
Comment![On the Move, Healthcare]
ACHN in Focus
more »
ACHN Related Articles
more »
ACHN News
more »
-
at MarketWatch.com (Mon, 4:22PM)
-
at MarketWatch.com (Apr 19, 2012)
-
at MarketWatch.com (Apr 19, 2012)
-
at MarketWatch.com (Feb 7, 2012)
-
at MarketWatch.com (Feb 1, 2012)
ACHN Press Releases and Filings
more »
-
GlobeNewswire (Mon, 7:00AM)
-
GlobeNewswire (May 18, 2012)
-
GlobeNewswire (May 15, 2012)
-
GlobeNewswire (May 9, 2012)
-
GlobeNewswire (May 9, 2012)
ACHN Latest Transcript
more »
Currently, there are no transcripts for ACHN.
ACHN Cramer
more »
Currently, there are no Cramer articles on ACHN.
ACHN Instablog posts
more »
ACHN vs. ETF Alternatives
Company Description
Currently, there's no company description for ACHN.